New Study Shows DHA (Docosahexaenoic Acid) Cuts Risk of Dementia
Statistics confirm that Americans have the lowest intake of DHA of any developed country. Doctors are now using Animi-3 to reliably deliver, in a controlled, predictable manner, DHA to different types of patients.
21/11/06 A new follow-up study to the Framingham Heart Study has determined that DHA (docosahexaenoic acid) significantly decreases the risk of developing all-cause dementia by 47 percent. Lead author Ernst J. Schaefer, M.D., Professor of Medicine at Tufts University School of Medicine, is also conducting a clinical trial for cardiovascular risk reduction and dementia on Animi-3, a prescription- only product with 350 mg of DHA.
Published in the November issue of Archives of Neurology, the follow-up study is the first to evaluate the role of plasma DHA in the occurrence of dementia and Alzheimer disease. Dr. Schaefer and his colleagues used a large study population of 899 subjects (median age 76) free of dementia at baseline. A follow-up period averaging nine years was used to determine the development of all-cause dementia and Alzheimer disease.
Statistics confirm that Americans have the lowest intake of DHA of any developed country. Doctors are now using Animi-3 to reliably deliver, in a controlled, predictable manner, DHA to different types of patients. The DHA in Animi-3 is all natural, meets stringent purity specification, and comes from a source that has earned USP approval.
"Animi-3 provides doctors with a reliable way of addressing the DHA deficiency, a clear risk factor associated with dementia that Dr. Schaefer's study has revealed," said PBM Pharmaceuticals Executive Vice President Jack Schramm, who is the co-inventor of the Animi-3 formula. "It is also interesting that most OTC fish oil products are predominately EPA [eicosapentaenoic acid], and Dr. Schaefer's study found no relationship between plasma EPA and dementia. Animi-3 is predominantly DHA."
